Format

Send to

Choose Destination
Pharmacol Rep. 2012;64(2):428-37.

Preclinical pharmacokinetics of radiolabelled hyaluronan.

Author information

1
Charles University in Prague, Faculty of Pharmacy in Hradec Kralove, Heyrovskeho 1203, CZ-500 05 Hradec Kralove, Czech Republic. Laznicek@faf.cuni.cz

Abstract

BACKGROUND:

Hyaluronan (HYA) is a high molecular weight glucosaminoglycan with a great perspective for medical applications. Because HYA is widespread in the body, it is difficult to determine the fate of exogenously administered HYA.

METHODS:

In this study, HYAof different molecular weights (0.1-1 MDa) was labelled with (99m)Tc, and the distribution profiles were determined after administrating the HYA to rats.

RESULTS:

After the intravenous administration of (99m)Tc-HYA, a rapid decrease in the radioactivity of blood samples was observed, presumably because of (99m)Tc-HYA uptake by the liver; only minimal signs of liver radioactivity washout were detected. After the oral administration of (99m)Tc-HYA, no significant absorption to the central compartment was found. A preliminary study using (14)C-HYA exhibited a different distribution profile than (99m)Tc-HYA because of the different administered dose and the fate of the degradation products. Even with (14)C-HYA, only traces of radioactivity were absorbed after oral administration.

CONCLUSION:

This paper provides quantitative information regarding the distribution parameters of radiolabelled HYA in preclinical experiments.

PMID:
22661195
DOI:
10.1016/s1734-1140(12)70784-3
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Institute of Pharmacology Polish Academy of Sciences
Loading ...
Support Center